Indication Covered

The report covers Myelodysplastic Syndromes (MDS) as a heterogeneous group of clonal hematopoietic stem cell disorders, with emphasis on its clinical burden, treatment patterns, therapeutic innovation, and commercial market development across the United States and China. MDS is primarily characterized by ineffective hematopoiesis, abnormal development of blood cells, persistent cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). The condition can range from lower-risk disease with mild or moderate blood-cell deficiencies to higher-risk disease with severe cytopenias, increased bone marrow blasts, and substantial risk of leukemic transformation, requiring supportive care, erythropoiesis-stimulating agents, hypomethylating agents, targeted therapies, and hematopoietic stem cell transplantation.

The indication scope includes major clinical manifestations and associated disease conditions relevant to treatment demand, including:

  • MDS with low blasts
  • MDS with increased blasts
  • MDS with low blasts and isolated del(5q)
  • MDS with SF3B1 mutation
  • Hypoplastic MDS
  • MDS with multilineage dysplasia

Lower-risk MDS remains an important focus because of its relatively larger treatment population, chronic anemia burden, transfusion dependence, and requirement for long-term disease management. The report also considers higher-risk MDS because of its increased risk of progression to AML, greater treatment intensity, and substantial unmet clinical need. Other difficult-to-treat manifestations, complications, or advanced forms, including transfusion-dependent anemia, severe thrombocytopenia, neutropenia, recurrent infections, iron overload, and MDS following hypomethylating agent failure, are evaluated as areas of continuing clinical need.

The treatment landscape covers supportive care, erythropoiesis-stimulating agents (ESAs), immunomodulatory agents, hypomethylating agents (HMAs), targeted therapies, and hematopoietic stem cell transplantation. Particular attention is given to advanced therapies targeting DNA methylation, telomerase activity, transforming growth factor-beta (TGF-β) signaling, and specific molecular abnormalities, as well as emerging oral hypomethylating agents, next-generation anemia treatments, and combination therapeutic approaches.

Epidemiology Parameters

MDS represents a significant chronic hematological malignancy burden across the United States and China. Epidemiological patterns vary substantially between countries because of differences in genetic susceptibility, environmental factors, healthcare access, disease awareness, diagnostic practices, bone marrow examination availability, and availability of hematologists and specialized diagnostic services.

ℹ To learn more about this report – Download Your Free Sample Report Here

The epidemiology assessment provides a structured evaluation of the MDS population from overall prevalence through diagnosis and treatment. Key parameters include:

  • Total MDS patient population
  • Prevalent population
  • Incidence population
  • Diagnosed patient population
  • Treated patient population
  • Untreated patient population
  • Treatment-eligible population
  • Disease severity distribution
  • Lower-risk MDS population
  • Intermediate-risk MDS population
  • Higher-risk MDS population
  • MDS with isolated del(5q) population
  • MDS with SF3B1 mutation population
  • Age distribution
  • Gender distribution
  • Diagnosis rate
  • Treatment rate
  • Treatment penetration
  • Regional disease burden
  • Epidemiological trends

The analysis distinguishes between the broader prevalent population and patients who are diagnosed and actively receiving treatment. This distinction is particularly important because a proportion of patients may remain undiagnosed, undertreated, or managed through transfusions and supportive interventions without receiving disease-modifying pharmaceutical treatment.

The report also evaluates the increasing recognition of MDS as a heterogeneous clonal hematological malignancy with a variable risk of progression to AML. Associated manifestations such as chronic anemia, transfusion dependence, iron overload, thrombocytopenia, neutropenia, recurrent infections, and bleeding complications can influence treatment decisions, disease monitoring, healthcare utilization, and long-term management strategies.

Patient Segmentation

The MDS patient population is segmented according to disease risk category, disease manifestation, treatment status, and therapeutic requirements. This approach provides a clearer understanding of the population eligible for different treatment categories and helps assess the potential addressable population for advanced therapies.

By Disease Severity

Lower-Risk MDS: Patients with lower-risk disease generally have relatively limited bone marrow blast percentages and a lower probability of progression to AML. They are primarily managed through supportive care, red blood cell transfusions, erythropoiesis-stimulating agents, lenalidomide, and luspatercept where appropriate. Treatment decisions are influenced by anemia severity, transfusion dependence, serum erythropoietin levels, cytogenetic abnormalities, previous treatment response, and patient preference.

Intermediate-Risk MDS: Patients with intermediate-risk disease may experience persistent cytopenias, increasing transfusion requirements, and greater risk of disease progression. Treatment approaches can include hypomethylating agents, targeted therapies for eligible molecular subgroups, supportive care, and consideration of transplantation. Increasing treatment expectations and disease-progression considerations can encourage movement toward more intensive systemic therapies.

Higher-Risk MDS: Patients with higher-risk disease, increased bone marrow blasts, substantial cytopenias, or an elevated probability of AML transformation are more likely to require hypomethylating agents, intensive chemotherapy in selected cases, targeted treatments, and allogeneic hematopoietic stem cell transplantation. This segment represents a major contributor to advanced MDS treatment demand.

By Disease Type

  • MDS with low blasts
  • MDS with increased blasts
  • MDS with isolated del(5q)
  • MDS with SF3B1 mutation
  • Hypoplastic MDS
  • MDS with multilineage dysplasia

By Treatment Status

  • Diagnosed and Treated
  • Diagnosed and Untreated
  • Undiagnosed

The treatment-status segmentation helps identify the gap between the total disease population and the population actively participating in healthcare treatment. Improvements in disease awareness, hematologist availability, bone marrow diagnostic capabilities, molecular testing, and healthcare access can gradually increase the diagnosed and treated population.

By Treatment Requirement

  • Supportive Care Candidates
  • Erythropoiesis-Stimulating Agent Candidates
  • Conventional Drug Therapy Candidates
  • Hypomethylating Agent Candidates
  • Targeted Therapy Candidates
  • Hematopoietic Stem Cell Transplantation Candidates

This segmentation helps evaluate how changes in treatment guidelines, physician preferences, reimbursement, molecular testing, and therapy availability can shift patients between conventional and advanced treatment categories.

Geographic Coverage

The report provides detailed market, epidemiology, treatment, and competitive analysis across 2 major markets:

  1. United States
  2. China

The geographic analysis considers differences in patient population, diagnosis rates, healthcare infrastructure, treatment accessibility, reimbursement, therapeutic penetration, regulatory environment, physician adoption, and competitive activity. These factors are particularly important because the commercial opportunity for MDS therapies differs considerably between the established pharmaceutical market of the United States and the rapidly developing healthcare and pharmaceutical market of China.

ℹ To learn more about this report – Download Your Free Sample Report Here

United States

The United States represents one of the most important MDS markets, supported by established hematology networks, advanced molecular diagnostic capabilities, strong pharmaceutical innovation, and broad availability of specialized hematological treatments. Hypomethylating agents, lenalidomide, luspatercept, and imetelstat have become important components of treatment for eligible patients. The approval of imetelstat in June 2024 expanded treatment options for adults with lower-risk MDS and transfusion-dependent anemia who have failed, lost response to, or are ineligible for ESAs.

The market is also characterized by significant competition between established therapies and newer treatments. Treatment selection is influenced by clinical efficacy, safety, transfusion independence, survival outcomes, dosing frequency, payer restrictions, patient preference, molecular characteristics, and prior treatment history. Continued development of next-generation anemia therapies, oral hypomethylating agents, and targeted treatments is expected to further intensify competition.

China

China represents a significant long-term growth opportunity because of its large population and increasing recognition of MDS as a clonal hematological malignancy requiring sustained management. Improvements in healthcare infrastructure, hematology specialist availability, molecular diagnostics, and clinical guidelines are supporting greater diagnosis and treatment access. Published Chinese epidemiological estimates indicate an MDS incidence of approximately 1.51 cases per 100,000 population, although differences in diagnostic practices and disease ascertainment can influence reported estimates.

The market is gradually experiencing increased adoption of advanced therapies, including hypomethylating agents and targeted treatments, although affordability, reimbursement coverage, treatment accessibility, and differences between urban and rural healthcare services remain important considerations. Expansion of innovative domestic pharmaceutical development, greater availability of generic medicines, and improvements in hematological cancer management may also increase competitive intensity.

Market Segmentation

The MDS market is segmented across drug class, treatment type, route of administration, patient risk category, and distribution channel. The segmentation captures both established treatment categories and emerging therapeutic approaches.

ℹ To learn more about this report – Download Your Free Sample Report Here

By Drug Class

Hypomethylating Agents
Hypomethylating agents represent a major segment of the MDS market because of their established role in higher-risk disease and their ability to influence abnormal DNA methylation associated with disease progression. These therapies selectively interfere with DNA methyltransferase activity and help restore normal gene-expression patterns involved in hematopoietic differentiation.

The hypomethylating agent segment includes azacitidine, decitabine, and oral decitabine/cedazuridine. Increasing physician familiarity, established clinical evidence, and their important role in higher-risk MDS continue to support utilization. Azacitidine remains an important treatment option because of its established clinical benefit in higher-risk patients.

Immunomodulatory and Anemia-Directed Agents
Immunomodulatory and anemia-directed agents represent an important segment because of growing demand for treatments that reduce transfusion dependence and improve hematological outcomes in lower-risk MDS. Unlike therapies primarily targeting higher-risk disease, these treatments focus on improving specific blood-cell deficiencies and reducing the clinical burden of chronic anemia.

The segment includes lenalidomide, luspatercept, and erythropoiesis-stimulating agents, where applicable. Continued clinical development and increasing treatment differentiation could increase the role of these therapies in patients requiring alternatives to repeated transfusions and conventional supportive care.

Targeted and Other Specialty Therapies
Targeted therapies represent an increasingly important segment because of growing understanding of the molecular abnormalities involved in MDS pathogenesis. These treatments are designed to interfere with specific biological mechanisms and provide additional options for patients with particular disease characteristics or inadequate responses to conventional treatment.

The category includes imetelstat, IDH1-targeted therapies in eligible molecular subgroups, and investigational agents targeting telomerase activity, TGF-β signaling, and other relevant biological pathways. Continued pipeline development and clinical differentiation could increase the role of targeted therapies in MDS management.

By Treatment Type

  • Supportive Care
  • Erythropoiesis-Stimulating Agents
  • Immunomodulatory Therapy
  • Hypomethylating Agent Therapy
  • Targeted Therapy
  • Hematopoietic Stem Cell Transplantation

Hypomethylating agent therapy remains central to the management of higher-risk MDS because of its established role in disease control and delaying progression. Supportive care and anemia-directed treatment continue to provide important options for lower-risk patients, while targeted therapies are expanding treatment possibilities for selected molecular and transfusion-dependent populations.

By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Other Routes

Intravenous and subcutaneous administration remain important within the MDS treatment landscape because azacitidine, decitabine, imetelstat, and other specialty therapies frequently require healthcare-professional administration. Oral administration is becoming increasingly attractive as oral decitabine/cedazuridine and other investigational treatment approaches expand. Oral therapies may improve treatment convenience and reduce the need for repeated hospital or clinic visits.

By Patient Risk Category

  • Lower-Risk MDS
  • Intermediate-Risk MDS
  • Higher-Risk MDS

Lower-risk MDS represents an important treatment population because of chronic anemia, transfusion dependence, and the requirement for long-term management. Higher-risk MDS represents a significant advanced treatment population because of its greater probability of AML transformation, more intensive treatment requirements, and higher unmet medical need. Intermediate-risk patients represent an important population for risk-adapted treatment selection and disease monitoring.

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

Distribution patterns vary by treatment type, country, reimbursement environment, and healthcare system. Hospital pharmacies are particularly relevant for intravenous and subcutaneous hypomethylating agents, specialty therapies, and transplantation-related treatment. Specialty pharmacies are important for high-cost targeted and specialty medicines, while retail and online channels may have greater relevance for selected oral therapies and supportive medications.

Market Dynamics

Growth Drivers

Increasing Adoption of Advanced Therapies
Advanced therapies continue to be one of the strongest growth drivers in the MDS market. Their ability to selectively interfere with abnormal DNA methylation, specific molecular abnormalities, and disease-related biological pathways has expanded treatment possibilities for patients with lower-risk and higher-risk disease.

The growing use of hypomethylating agents, luspatercept, lenalidomide, and imetelstat is particularly important as physicians increasingly consider transfusion independence, hematological response, treatment durability, safety, and overall survival when selecting therapies. Expanded clinical experience and improved physician familiarity are also supporting adoption.

Advancement in Disease Biology-Based Drug Development
Advances in understanding the molecular mechanisms underlying MDS have created opportunities for more precise therapeutic intervention. Pharmaceutical companies are increasingly investing in therapies designed to selectively target abnormal DNA methylation, telomerase activity, TGF-β signaling, and specific genetic mutations rather than relying solely on conventional treatment approaches.

Development activity is focused on novel molecular targets, oral hypomethylating agents, next-generation anemia therapies, improved treatment durability, combination regimens, and potentially more personalized approaches to treatment selection. These developments are expected to increase therapeutic competition.

Increasing Healthcare Access in China
Improving healthcare infrastructure and rising healthcare expenditure are increasing access to MDS diagnosis and treatment in China. Expansion of hematology specialist networks, improvements in molecular testing, and greater disease awareness are also helping identify patients who previously remained untreated or undiagnosed.

China represents an important growth opportunity because of its large population and expanding domestic pharmaceutical industry. Increased reimbursement, wider availability of advanced therapies, and development of cost-effective treatment options could accelerate market penetration.

Growing Recognition of MDS-Associated Clinical Burden
The increasing understanding of MDS as a heterogeneous clonal hematological malignancy is encouraging more comprehensive disease management. Recognition of complications such as chronic anemia, transfusion dependence, iron overload, recurrent infections, bleeding events, and progression to AML can encourage earlier diagnosis, specialist management, and continued treatment monitoring.

This shift can increase treatment intensity and create demand for therapies capable of achieving broader and more sustained hematological improvement and disease control.

Market Restraints

High Cost of Advanced Therapies
Targeted therapies, specialty medicines, and other advanced treatment approaches often carry substantially higher treatment costs than conventional supportive therapies. High costs can create affordability challenges for patients and increase pressure on healthcare payers.

In China, limited reimbursement coverage for certain advanced treatments and high out-of-pocket expenditure can restrict access to innovative treatment. Cost considerations may therefore continue to influence treatment selection and delay the adoption of newer therapies.

Treatment Accessibility Gap
Unequal access to hematologists, specialized hematology centers, bone marrow examination, molecular diagnostic services, and advanced medicines remains a major challenge. Rural and underserved populations may experience longer diagnostic delays and fewer treatment options.

Differences in healthcare infrastructure between regions can therefore result in significant variations in diagnosis, treatment penetration, and disease outcomes. Limited availability of specialized transplantation facilities can further restrict access to potentially curative treatment.

Variable Patient Response
Although advanced therapies have significantly improved MDS management, treatment response is not uniform across patients. Some individuals may experience inadequate initial response, secondary loss of efficacy, treatment resistance, intolerance, persistent transfusion dependence, or treatment discontinuation.

The need to switch therapies can increase healthcare utilization and creates continuing demand for treatments offering durable hematological responses, improved safety, and predictable disease control. Treatment failure following hypomethylating agent therapy remains a particularly important unmet medical need.

Competitive Landscape

The global MDS market across the United States and China is characterized by competition among pharmaceutical companies with established hematology and oncology portfolios and emerging developers focused on differentiated mechanisms and treatment approaches.

Leading companies covered in the competitive assessment include:

  • Bristol Myers Squibb
  • Geron Corporation
  • Taiho Pharmaceutical
  • Otsuka Pharmaceutical
  • Jazz Pharmaceuticals
  • AbbVie
  • Novartis
  • Keros Therapeutics
  • Hengrui Pharmaceuticals
  • Ascentage Pharma

Competition is increasingly focused on demonstrating superior or differentiated clinical outcomes rather than simply introducing additional therapies within existing drug classes. Companies are investing in novel mechanisms, improved dosing schedules, oral administration, transfusion independence, treatment durability, safety profiles, and lifecycle expansion.

The competitive environment is also being influenced by generic availability, pricing pressure, reimbursement restrictions, and physician familiarity with established products. Hypomethylating agents, TGF-β pathway inhibitors, telomerase inhibitors, and other targeted approaches are expected to remain important areas of competition.

Pipeline innovation is another major competitive factor. Companies with strong clinical-development capabilities and diversified hematology and oncology portfolios may be better positioned to respond to changing treatment preferences and emerging unmet needs. The development of therapies for lower-risk MDS with transfusion-dependent anemia and higher-risk MDS following hypomethylating agent failure is expected to remain particularly important.

Recent Developments

  • September 2026 – Taiho advances oral azacitidine and cedazuridine development: Taiho Pharmaceutical and Taiho Oncology reported positive topline results from the Phase III AZTOUND trial evaluating ASTX030, an orally available azacitidine and cedazuridine combination, in patients with MDS or chronic myelomonocytic leukemia. The study met its primary pharmacokinetic exposure endpoint, with a safety profile consistent with parenteral azacitidine. The development highlights the industry's increasing interest in oral hypomethylating therapies and their potential to provide greater treatment convenience and reduce administration-related burdens.
  • July 2026 – Keros Therapeutics advances elritercept clinical development: Keros Therapeutics reported the initiation of the Phase III ELRiSE MDS clinical trial evaluating elritercept against epoetin alfa in patients with anemia associated with lower-risk MDS. The program is being developed in collaboration with Takeda and reflects continued investment in TGF-β superfamily pathway modulation designed to address persistent anemia, reduce transfusion requirements, and improve hematological outcomes in lower-risk MDS patients.

Report Coverage

The report provides a comprehensive assessment of the MDS market across the two specified major markets, the United States and China. It integrates epidemiological analysis with commercial market assessment to provide a broader understanding of the current and future treatment landscape.

The study covers:

  • Indication Covered
  • Epidemiology Parameters
  • Patient Segmentation
  • Geographic Coverage
  • Market Segmentation
  • Units of Measurement
  • Study Period
  • Data Sources
  • Companies Covered
  • Report Deliverables
  • Out of Scope
  • Customization